Innocrin Pharmaceuticals (United States)

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

John D. Norris, Stephanie J. Ellison, Jennifer G. Baker et al. · Journal of Clinical Investigation · 2017 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer

Jessica L. Christenson, Kathleen O’Neill, Michelle M. Williams et al. · Molecular Cancer Therapeutics · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

Aditya Bardia, Ayca Gucalp, Noashir DaCosta et al. · Breast Cancer Research and Treatment · 2018 · 43 citations

Medicine, Oncology, Pharmacology +15

Silica xerogels as a delivery system for the controlled release of different molecular weight heparins

Norberto Roveri, Margherita Morpurgo, Barbara Palazzo et al. · Analytical and Bioanalytical Chemistry · 2004 · 40 citations

Pharmacy, Molecular Pharmaceutics, Pharmaceutics +17

Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells

Anna R. Michmerhuizen, Benjamin C. Chandler, Eric Olsen et al. · Frontiers in Endocrinology · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17